The Great Weight Race: Can New Contenders Navigate the Treacherous Path of Next-Gen Obesity Drugs?
The Quiet Revolution: How the FDA is Finally Taking Aim at Sky-High Drug Prices
The Quiet Revolution: How Federal Officials Are Fighting for Cheaper Biotech Drugs
The GLP-1 Gold Rush: Why Morgan Stanley Just Downgraded Novo Nordisk Amid Fierce Competition
The Race for the Next Weight Loss Breakthrough: Chinese Biotechs Challenge Global Giants